应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
00460 四环医药
未开盘 10-02 16:08:34
0.690
+0.040
+6.15%
最高
0.700
最低
0.650
成交量
3,799万
今开
0.650
昨收
0.650
日振幅
7.69%
总市值
64.31亿
流通市值
64.31亿
总股本
93.20亿
成交额
2,594万
换手率
0.41%
流通股本
93.20亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
四环医药盘中异动 早盘快速上涨6.15%
市场透视 · 10-02 11:11
四环医药盘中异动 早盘快速上涨6.15%
港股异动 | 四环医药(00460)涨超6% 注射用A型肉毒毒素独家销售协议续约至2030年年底
智通财经 · 09-30 14:55
港股异动 | 四环医药(00460)涨超6% 注射用A型肉毒毒素独家销售协议续约至2030年年底
四环医药(00460)上涨10.34%,报0.64元/股
金融界 · 09-30 13:05
四环医药(00460)上涨10.34%,报0.64元/股
四环医药盘中异动 早盘股价大涨6.90%报0.620港元
市场透视 · 09-30 09:30
四环医药盘中异动 早盘股价大涨6.90%报0.620港元
【港股通】四环医药(00460):注射用A型肉毒毒素独家销售协议续约至2030年年底
金吾财讯 · 09-27
【港股通】四环医药(00460):注射用A型肉毒毒素独家销售协议续约至2030年年底
四环医药(00460):肉毒毒素乐提葆®独家销售协议续约至2030年年底
智通财经 · 09-27
四环医药(00460):肉毒毒素乐提葆®独家销售协议续约至2030年年底
四环医药(00460.HK):肉毒毒素产品独家销售协议续约至2030年年底
阿斯达克财经 · 09-27
四环医药(00460.HK):肉毒毒素产品独家销售协议续约至2030年年底
四环医药09月26日遭主力抛售320万元 环比增加932.26%
市场透视 · 09-26
四环医药09月26日遭主力抛售320万元 环比增加932.26%
四环医药(00460)出现大手卖出300万股,成交价$0.55,涉资165万
阿斯达克财经 · 09-25
四环医药(00460)出现大手卖出300万股,成交价$0.55,涉资165万
四环医药盘中异动 早盘快速上涨5.88%报0.540港元
市场透视 · 09-13
四环医药盘中异动 早盘快速上涨5.88%报0.540港元
四环医药(00460)股价上升5.882%,现价港币$0.54
阿斯达克财经 · 09-13
四环医药(00460)股价上升5.882%,现价港币$0.54
南向资金9月12日净卖出四环医药271.10万股 连续3日减持
市场透视 · 09-13
南向资金9月12日净卖出四环医药271.10万股 连续3日减持
四环医药(00460)下跌5.45%,报0.52元/股
金融界 · 09-09
四环医药(00460)下跌5.45%,报0.52元/股
南向资金9月5日净卖出四环医药103.80万股 连续3日减持
市场透视 · 09-09
南向资金9月5日净卖出四环医药103.80万股 连续3日减持
医美产业链上游半年报|爱美客增长失速、华熙生物业绩双降垫底医美三剑客 四环医药延续亏损
新浪证券 · 09-06
医美产业链上游半年报|爱美客增长失速、华熙生物业绩双降垫底医美三剑客 四环医药延续亏损
四环医药(0460.HK):医美业务收入大增66.4%,转型显效开启加速增长
格隆汇 · 09-05
四环医药(0460.HK):医美业务收入大增66.4%,转型显效开启加速增长
四环医药发布中期业绩 医美产品的收益约3.23亿元同比上升约66.4%
新浪港股 · 08-30
四环医药发布中期业绩 医美产品的收益约3.23亿元同比上升约66.4%
【港股通】四环医药(00460)中期亏损收窄32.67% 派中期股息2.1港仙
金吾资讯 · 08-30
【港股通】四环医药(00460)中期亏损收窄32.67% 派中期股息2.1港仙
四环医药(00460)发布中期业绩 医美产品的收益约3.23亿元 同比上升约66.4% 美颜空间产品获得市场的高度认可
智通财经网 · 08-30
四环医药(00460)发布中期业绩 医美产品的收益约3.23亿元 同比上升约66.4% 美颜空间产品获得市场的高度认可
四环医药(00460.HK):附属减重药物临床试验申请获批
阿斯达克财经 · 08-30
四环医药(00460.HK):附属减重药物临床试验申请获批
加载更多
公司概况
公司名称:
四环医药
所属市场:
SEHK
上市日期:
--
主营业务:
四环医药控股集团有限公司是一家从事药品业务的香港投资控股公司。该公司主要在中国从事研发、制造及销售药品。其产品覆盖心脑血管、中枢神经系统、新陈代谢、肿瘤及抗感染领域。其心脑血管产品包括克林澳、安捷利及欧迪美等。其非心脑血管产品包括仁澳、甲硝唑及罗沙替丁等。
发行价格:
--
{"stockData":{"symbol":"00460","market":"HK","secType":"STK","nameCN":"四环医药","latestPrice":0.69,"timestamp":1727856514025,"preClose":0.65,"halted":0,"volume":37988231,"delay":0,"floatShares":9319999206,"shares":9319999206,"eps":-0.006410941,"marketStatus":"未开盘","marketStatusCode":0,"change":0.04,"latestTime":"10-02 16:08:34","open":0.65,"high":0.7,"low":0.65,"amount":25939427,"amplitude":0.076923,"askPrice":0.7,"askSize":410000,"bidPrice":0.69,"bidSize":139000,"shortable":3,"etf":0,"ttmEps":-0.004514141170989284,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1727919000000},"adr":0,"adjPreClose":0.65,"dividendRate":0.030384,"openAndCloseTimeList":[[1727832600000,1727841600000],[1727845200000,1727856000000]],"volumeRatio":1.0839099870827211,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00460","defaultTab":"news","newsList":[{"id":"2472698225","title":"四环医药盘中异动 早盘快速上涨6.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2472698225","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472698225?lang=zh_cn&edition=full","pubTime":"2024-10-02 11:11","pubTimestamp":1727838711,"startTime":"0","endTime":"0","summary":"2024年10月02日早盘11时11分,四环医药股票出现波动,股价大幅拉升6.15%。截至发稿,该股报0.690港元/股,成交量1280.82万股,换手率0.14%,振幅6.15%。四环医药股票所在的药品行业中,整体涨幅为0.56%。其相关个股中,中国医疗集团、艾美疫苗、精优药业涨幅较大,振幅较大的相关个股有中国医疗集团、艾美疫苗、精优药业,振幅分别为76.36%、42.11%、30.30%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241002111151ab676616&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241002111151ab676616&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1593","00460","BK1600","BK1191"],"gpt_icon":0},{"id":"2471826537","title":"港股异动 | 四环医药(00460)涨超6% 注射用A型肉毒毒素独家销售协议续约至2030年年底","url":"https://stock-news.laohu8.com/highlight/detail?id=2471826537","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471826537?lang=zh_cn&edition=full","pubTime":"2024-09-30 14:55","pubTimestamp":1727679358,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,四环医药(00460)涨超10%,截至发稿,涨10.34%,报0.64港元,成交额3373.48万港元。消息面上,四环医药发布公告,与韩国生物制药公司Hugel, Inc.签署的关于注射用A型肉毒毒素(乐提葆)的独家销售协议,经协议双方一致确认,已续约至2030年年底。据介绍,乐提葆是中国市场中第四个获批上市的肉毒毒素产品,也是目前中国市场上唯一一个获批的韩国肉毒毒素产品,该产品由Hugel, Inc.研发生产。今年上半年,乐提葆在中国的销售收入按年增长逾50%。根据市场信息显示,乐提葆在中国的市场占有率已超过10%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1188870.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1593","00460","BK1515","BK1600"],"gpt_icon":0},{"id":"2471410048","title":"四环医药(00460)上涨10.34%,报0.64元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2471410048","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471410048?lang=zh_cn&edition=full","pubTime":"2024-09-30 13:05","pubTimestamp":1727672732,"startTime":"0","endTime":"0","summary":"9月30日,四环医药(00460)盘中上涨10.34%,截至13:05,报0.64元/股,成交1684.45万元。四环医药控股集团有限公司是中国处方药市场的领先制药企业,主要业务为生产和销售心脑血管处方药物,自2007年起一直是全国最大的心脑血管处方药物供应商。公司的关键经营数据包括独特的销售模式、全国覆盖的销售网络、多元化的产品组合以及强大的研发能力。截至2024年中报,四环医药营业总收入9.5亿元、净利润-3342.4万元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/09/30130543649045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1515","BK1600","BK1593","00460","BK1191"],"gpt_icon":0},{"id":"2471153738","title":"四环医药盘中异动 早盘股价大涨6.90%报0.620港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2471153738","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471153738?lang=zh_cn&edition=full","pubTime":"2024-09-30 09:30","pubTimestamp":1727659820,"startTime":"0","endTime":"0","summary":"2024年09月30日早盘09时30分,四环医药股票出现波动,股价大幅拉升6.90%。截至发稿,该股报0.620港元/股,成交量173.6万股,换手率0.02%,振幅3.45%。资金方面,该股资金流入35.787万港元,流出8.09万港元。四环医药股票所在的药品行业中,整体涨幅为0.09%。其相关个股中,康龙化成、凯莱英、艾美疫苗涨幅较大,振幅较大的相关个股有四环医药、艾美疫苗、和黄医药,振幅分别为3.45%、3.15%、2.65%。消息层面,截至09时30分,四环医药股票正面舆情新闻比例6.25%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240930093020ab66e741&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240930093020ab66e741&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","00460","BK1515","BK1600","BK1191"],"gpt_icon":0},{"id":"2470427447","title":"【港股通】四环医药(00460):注射用A型肉毒毒素独家销售协议续约至2030年年底","url":"https://stock-news.laohu8.com/highlight/detail?id=2470427447","media":"金吾财讯","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470427447?lang=zh_cn&edition=full","pubTime":"2024-09-27 12:43","pubTimestamp":1727412226,"startTime":"0","endTime":"0","summary":"金吾财讯 | 四环医药(00460)公告,集团与韩国生物制药公司Hugel,Inc.签署的关于注射用A型肉毒毒素(商品名:乐提葆,规格:100U及50U)的独家销售协议,经协议双方一致确认,已续约至2030年年底。乐提葆®是中国市场中第四个获批上市的肉毒毒素产品,也是目前中国市场上唯一一个获批的韩国肉毒毒素产品。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/NzBjNjFmNjI4ZDIyNTQ0NjcwODk0MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NzBjNjFmNjI4ZDIyNTQ0NjcwODk0MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1945001","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","HSCEI","BK1593","BK1191","HSTECH","00460","YANG","BK1600"],"gpt_icon":0},{"id":"2470424587","title":"四环医药(00460):肉毒毒素乐提葆®独家销售协议续约至2030年年底","url":"https://stock-news.laohu8.com/highlight/detail?id=2470424587","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470424587?lang=zh_cn&edition=full","pubTime":"2024-09-27 12:34","pubTimestamp":1727411694,"startTime":"0","endTime":"0","summary":"智通财经APP讯,四环医药 公布,该集团与韩国生物制药公司Hugel,Inc.签署的关于注射用A型肉毒毒素的独家销售协议,经协议双方一致确认,已续约至2030年年底。自乐提葆于2020年在中国获批、2021年正式开始上市销售后,就以其高品质、高性价比的特点获得广大医美消费者的认可。2024年上半年,乐提葆在中国的销售收入持续维持高增长,同比增长超过50%。根据市场信息显示,乐提葆在中国的市场占有率已超过10%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1187998.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","00460","BK1515","BK1593","BK1600"],"gpt_icon":0},{"id":"2470742992","title":"四环医药(00460.HK):肉毒毒素产品独家销售协议续约至2030年年底","url":"https://stock-news.laohu8.com/highlight/detail?id=2470742992","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470742992?lang=zh_cn&edition=full","pubTime":"2024-09-27 12:27","pubTimestamp":1727411220,"startTime":"0","endTime":"0","summary":"四环医药(00460.HK) 公布,与韩国生物制药公司Hugel, Inc.签署的关于注射用A型肉毒毒素(乐提葆)的独家销售协议,经协议双方一致确认,已续约至2030年年底。据介绍,乐提葆是中国市场中第四个获批上市的肉毒毒素产品,也是目前中国市场上唯一一个获批的韩国肉毒毒素产品,该产品由Hugel, Inc.研发生产。今年上半年,乐提葆在中国的销售收入按年增长逾50%。根据市场信息显示,乐提葆在中国的市场占有率已超过10%。(js/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-09-26 16:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220413154450154_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220413154450154_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1384477/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1515","BK1593","00460","BK1600","BK1191"],"gpt_icon":0},{"id":"2470209096","title":"四环医药09月26日遭主力抛售320万元 环比增加932.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2470209096","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470209096?lang=zh_cn&edition=full","pubTime":"2024-09-26 16:17","pubTimestamp":1727338626,"startTime":"0","endTime":"0","summary":"09月26日, 四环医药股价涨3.64%,报收0.57元,成交金额1926万元,换手率0.37%,振幅3.64%,量比3.87。四环医药今日主力资金净流出320万元,上一交易日主力净流出31万元,今日环比增加932.26%。该股近5个交易日上涨3.70%,主力资金累计净流出301万元;近20日主力资金累计净流出302万元,其中净流出天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240926162023957ed6e2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240926162023957ed6e2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00460","BK1593","BK1600","BK1515","BK1191"],"gpt_icon":0},{"id":"2470437402","title":"四环医药(00460)出现大手卖出300万股,成交价$0.55,涉资165万","url":"https://stock-news.laohu8.com/highlight/detail?id=2470437402","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470437402?lang=zh_cn&edition=full","pubTime":"2024-09-25 13:23","pubTimestamp":1727241780,"startTime":"0","endTime":"0","summary":"[大手成交]四环医药(00460)在下午01:23出现大手卖出,成交量为300万,成交价为港币$0.55,涉资165万。至目前为止,股价升1.818%,今日最高价为$0.57,而最低价为$0.55,总成交量为1.47千万股,总成交金额港币$817.762万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145550051_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145550051_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2409257786/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1515","BK1191","BK1600","00460","BK1593"],"gpt_icon":0},{"id":"2467967761","title":"四环医药盘中异动 早盘快速上涨5.88%报0.540港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2467967761","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467967761?lang=zh_cn&edition=full","pubTime":"2024-09-13 10:24","pubTimestamp":1726194285,"startTime":"0","endTime":"0","summary":"2024年09月13日早盘10时24分,四环医药股票出现异动,股价急速拉升5.88%。截至发稿,该股报0.540港元/股,成交量634.3万股,换手率0.07%,振幅5.88%。资金方面,该股资金流入329.965万港元,流出2.056万港元。四环医药股票所在的药品行业中,整体涨幅为0.36%。其相关个股中,联康生物科技集团、四环医药、凯莱英涨幅较大,振幅较大的相关个股有联康生物科技集团、君圣泰医药-B、顺腾国际控股,振幅分别为10.29%、8.79%、8.11%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409131024459719b351&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409131024459719b351&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1600","BK1515","00460","BK1191"],"gpt_icon":0},{"id":"2467858764","title":"四环医药(00460)股价上升5.882%,现价港币$0.54","url":"https://stock-news.laohu8.com/highlight/detail?id=2467858764","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467858764?lang=zh_cn&edition=full","pubTime":"2024-09-13 10:24","pubTimestamp":1726194240,"startTime":"0","endTime":"0","summary":"[上升股]四环医药(00460) 股价在上午10:24比前收市价上升5.882%,现股价为港币$0.54。至目前为止,今日最高价为$0.54,而最低价为$0.51。总成交量为634.3万股,总成交金额为港币$332.021万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152549604_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152549604_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2409132089/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1515","BK1593","00460","BK1191","BK1600"],"gpt_icon":0},{"id":"2467655017","title":"南向资金9月12日净卖出四环医药271.10万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2467655017","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467655017?lang=zh_cn&edition=full","pubTime":"2024-09-13 09:30","pubTimestamp":1726191006,"startTime":"0","endTime":"0","summary":"9月12日,南向资金减持四环医药271.10万股连续3日减持。截止当日收盘,港股通共持有四环医药81023.40万股,占流通股8.68%。四环医药近5个交易日下跌7.27%,港股通累计减持626.90万股;近20个交易日下跌3.77%,港股通累计减持1395.40万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409130930369ef92c99&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409130930369ef92c99&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","00460","BK1515","BK1600","BK1191"],"gpt_icon":0},{"id":"2466136663","title":"四环医药(00460)下跌5.45%,报0.52元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2466136663","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466136663?lang=zh_cn&edition=full","pubTime":"2024-09-09 14:07","pubTimestamp":1725862075,"startTime":"0","endTime":"0","summary":"9月9日,四环医药(00460)盘中下跌5.45%,截至14:07,报0.52元/股,成交483.67万元。四环医药控股集团有限公司是中国处方药市场的领先制药企业,主要业务为生产和销售心脑血管处方药物,自2007年起一直是全国最大的心脑血管处方药物供应商。公司的关键经营数据包括独特的销售模式、全国覆盖的销售网络、多元化的产品组合以及强大的研发能力。截至2024年中报,四环医药营业总收入9.5亿元、净利润-3342.4万元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/09/09140743112765.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","BK1515","BK1600","BK1593","00460"],"gpt_icon":0},{"id":"2466690436","title":"南向资金9月5日净卖出四环医药103.80万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2466690436","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466690436?lang=zh_cn&edition=full","pubTime":"2024-09-09 09:30","pubTimestamp":1725845408,"startTime":"0","endTime":"0","summary":"9月5日,南向资金减持四环医药103.80万股连续3日减持。截止当日收盘,港股通共持有四环医药81546.50万股,占流通股8.73%。四环医药近5个交易日上涨3.77%,港股通累计减持431.20万股;近20个交易日上涨1.85%,港股通累计减持914.10万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409090930319eed1a9f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409090930319eed1a9f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1515","BK1600","BK1593","00460"],"gpt_icon":0},{"id":"2465966587","title":"医美产业链上游半年报|爱美客增长失速、华熙生物业绩双降垫底医美三剑客 四环医药延续亏损","url":"https://stock-news.laohu8.com/highlight/detail?id=2465966587","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2465966587?lang=zh_cn&edition=full","pubTime":"2024-09-06 17:07","pubTimestamp":1725613629,"startTime":"0","endTime":"0","summary":"在医美产业链上游上市公司业绩披露中,仅有爱美客、昊海生科、华东医药营收净利润双增,江苏吴中增收不增利、华熙生物业绩双降、四环医药营收下滑且延续亏损。相较以往,爱美客业绩增速显著放缓。或是受业绩增速大幅下降影响,爱美客半年报发布次日,股价跌幅超12%。2024年上半年,华熙生物业绩双降,共实现营收28.1亿元,同比下降了8.61%;实现净利润3.42亿元,同比下降了19.51%,同时公司销售净利率进一步下降至12.11%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409061707189ee5468f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409061707189ee5468f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00460","BK1191","BK1600","BK1515","BK1593"],"gpt_icon":0},{"id":"2465519803","title":"四环医药(0460.HK):医美业务收入大增66.4%,转型显效开启加速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2465519803","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2465519803?lang=zh_cn&edition=full","pubTime":"2024-09-05 15:15","pubTimestamp":1725520508,"startTime":"0","endTime":"0","summary":"医美转型兑现落地,医美业务收入大增66.4%","market":"hk","thumbnail":"https://img7.gelonghui.com/column/4.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/4.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/1007633","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1191","BK1593","00460","BK1515","BK1600"],"gpt_icon":0},{"id":"2463736302","title":"四环医药发布中期业绩 医美产品的收益约3.23亿元同比上升约66.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2463736302","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463736302?lang=zh_cn&edition=full","pubTime":"2024-08-30 12:54","pubTimestamp":1724993684,"startTime":"0","endTime":"0","summary":"四环医药发布截至2024年6月30日止6个月业绩,该集团期内取得收益9.5亿元;公司拥有人应占亏损3342.4万元;每股基本亏损0.36分;拟派发中期股息每股1.9分。 来自创新药及其他药品的收益约为2960万元,同比上升了约85.0%,主要由于轩竹生物科技股份有限公司自研的一类新药安奈拉唑钠于2023年下半年获批上市并开始产生收入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-08-30/doc-incmkytp9119889.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-08-30/doc-incmkytp9119889.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1593","00460","BK1515","BK1600","BK1191"],"gpt_icon":0},{"id":"2463278321","title":"【港股通】四环医药(00460)中期亏损收窄32.67% 派中期股息2.1港仙","url":"https://stock-news.laohu8.com/highlight/detail?id=2463278321","media":"金吾资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463278321?lang=zh_cn&edition=full","pubTime":"2024-08-30 12:26","pubTimestamp":1724991997,"startTime":"0","endTime":"0","summary":"金吾财讯 | 四环医药 公布,截至2024年6月30日止六个月,公司拥有人应占亏损3342.4万元,同比亏损收窄32.67%,每股基本亏损0.36分。派中期股息每股1.9分。其中来自医美产品的收益约3.23亿元,同比上升约66.4%;来自仿制药的收益约5.97亿元,同比下降约29.4%;来自创新药及其他药品的收益约2960万元,同比上升约85.0%。期内,集团毛利6.09亿元,同比减少18.62%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408301227159f67a22b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408301227159f67a22b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HSTECH","BK1515","00460","HSCEI","BK1600","BK1191","07226","BK1593"],"gpt_icon":0},{"id":"2463222087","title":"四环医药(00460)发布中期业绩 医美产品的收益约3.23亿元 同比上升约66.4% 美颜空间产品获得市场的高度认可","url":"https://stock-news.laohu8.com/highlight/detail?id=2463222087","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463222087?lang=zh_cn&edition=full","pubTime":"2024-08-30 12:12","pubTimestamp":1724991143,"startTime":"0","endTime":"0","summary":"公告称,来自医美产品的收益约为3.23亿元,同比上升约66.4%,主要由于期内集团旗下医美平台美颜空间加大与多家医美机构的战略合作以及大力推广营销战略3.0版本升级取得阶段性的成功,产品获得市场的高度认可,从而推动医美销售收入大幅增长。目前医美平台美颜空间已有20余款产品获批上市,其中包括5款产品已上市销售,另外有40余款产品处于报产审批或在研阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408301215259f679b36&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408301215259f679b36&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1600","BK1515","00460","BK1191"],"gpt_icon":0},{"id":"2463622013","title":"四环医药(00460.HK):附属减重药物临床试验申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2463622013","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463622013?lang=zh_cn&edition=full","pubTime":"2024-08-30 12:12","pubTimestamp":1724991120,"startTime":"0","endTime":"0","summary":"四环医药(00460.HK) 公布,旗下非全资附属公司开发的司美格鲁肽注射液用于超重或肥胖的临床试验申请已获国家药监局批准,这是该产品继成人2型糖尿病患者的血糖控制适应症后,获得临床试验批准的第二个适应症。该产品同时也是公司首个获得临床试验批准的减重药物。(vc/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-08-29 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220413154446706_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220413154446706_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1377607/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["03347","BK1583","00460","BK1191","BK1576","BK1600","BK1515","BK1141","BK1593"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sihuanpharm.com.cn","stockEarnings":[{"period":"1week","weight":0.3019},{"period":"1month","weight":0.3019},{"period":"3month","weight":0.3269},{"period":"6month","weight":0.3772},{"period":"1year","weight":0.2343},{"period":"ytd","weight":0.1022}],"compareEarnings":[{"period":"1week","weight":0.1733},{"period":"1month","weight":0.2686},{"period":"3month","weight":0.2449},{"period":"6month","weight":0.342},{"period":"1year","weight":0.295},{"period":"ytd","weight":0.3165}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"四环医药控股集团有限公司是一家从事药品业务的香港投资控股公司。该公司主要在中国从事研发、制造及销售药品。其产品覆盖心脑血管、中枢神经系统、新陈代谢、肿瘤及抗感染领域。其心脑血管产品包括克林澳、安捷利及欧迪美等。其非心脑血管产品包括仁澳、甲硝唑及罗沙替丁等。","yearOnYearQuotes":[{"month":1,"riseRate":0.615385,"avgChangeRate":0.124205},{"month":2,"riseRate":0.571429,"avgChangeRate":0.002117},{"month":3,"riseRate":0.357143,"avgChangeRate":-0.025539},{"month":4,"riseRate":0.538462,"avgChangeRate":0.029608},{"month":5,"riseRate":0.384615,"avgChangeRate":-0.005384},{"month":6,"riseRate":0.538462,"avgChangeRate":-0.006997},{"month":7,"riseRate":0.538462,"avgChangeRate":-0.005865},{"month":8,"riseRate":0.461538,"avgChangeRate":-0.024169},{"month":9,"riseRate":0.153846,"avgChangeRate":-0.057211},{"month":10,"riseRate":0.615385,"avgChangeRate":0.033593},{"month":11,"riseRate":0.538462,"avgChangeRate":0.020634},{"month":12,"riseRate":0.461538,"avgChangeRate":-0.010221}],"exchange":"SEHK","name":"四环医药","nameEN":"SIHUAN PHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"四环医药(00460)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供四环医药(00460)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"四环医药,00460,四环医药股票,四环医药股票老虎,四环医药股票老虎国际,四环医药行情,四环医药股票行情,四环医药股价,四环医药股市,四环医药股票价格,四环医药股票交易,四环医药股票购买,四环医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"四环医药(00460)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供四环医药(00460)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}